Nizatidine
- Generic Name
- Nizatidine
- Brand Names
- Axid
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N5O2S2
- CAS Number
- 76963-41-2
- Unique Ingredient Identifier
- P41PML4GHR
- Background
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
- Associated Conditions
- Duodenal Ulcer, Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Helicobacter Pylori Infection, Peptic Ulcer Disease, Stress Ulcers
- Associated Therapies
- -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Adil Bharucha
- Target Recruit Count
- 24
- Registration Number
- NCT02232308
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
- First Posted Date
- 2010-07-14
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 26
- Registration Number
- NCT01161927
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
- First Posted Date
- 2010-07-14
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 26
- Registration Number
- NCT01161940
Weight Gain Management in Patients With Schizophrenia
- Conditions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 74
- Registration Number
- NCT00486005
- Locations
- 🇧🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rio de Janeiro, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.